Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20391673 | 0.73 | CYP2A6 (0.58) | CYP2A6IDO1MAPTNPSR1CYP1A2 | |
| SCHEMBL5159704 | 0.73 | CYP2A6 (0.58) | CYP2A6NPSR1 | |
| SCHEMBL1335177 | 0.73 | CYP2A6 (0.58) | CYP2A6IDO1MAPTCYP2C19 | |
| SCHEMBL20391286 | 0.73 | CYP2A6 (0.58) | CYP2A6IDO1MAPTNPSR1CYP1A2 | |
| SCHEMBL29952897 | 0.73 | CYP2A6 (0.58) | CYP2A6MAPT | |
| SCHEMBL286735 | 0.73 | CYP2A6 (0.58) | CYP2A6MAPT | |
| SCHEMBL5379757 | 0.73 | CYP2A6 (0.58) | CYP2A6MAPT | |
| SCHEMBL13237429 | 0.73 | CYP2A6 (0.58) | CYP2A6IDO1MAPTNPSR1CYP1A2 | |
| SCHEMBL4273824 | 0.73 | CYP2A6 (0.58) | CYP2A6 | |
| SCHEMBL10300655 | 0.72 | TTR (0.40) | MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-8217028-B2 | 1,2,4-oxadiazole indole compounds | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | CYP2A6 3412/4885IDO1 2596/4885MAPT 3388/4885 |
| US-20100029729-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CYP2A6 142/4885IDO1 1294/4885MAPT 1092/4885 |
| US-20100010053-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CYP2A6 142/4885IDO1 1294/4885MAPT 1092/4885 |
| US-20110086839-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | CYP2A6 142/4885IDO1 1294/4885MAPT 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.